Pathology: mCRC - 1st line (L1); mCRC - 2nd line (L2);
| mCRC - 1st line (L1) | mCRC - 2nd line (L2) | ||||
| KEYNOTE-177, 2020 | IMblaze-370 (A ; all population), 2019 | IMblaze-370 (AC ; all population), 2019 | CO.26 study, 2020 | ||
| pembrolizumab alone | 1 | T1 | |||
| durvalumab plus tremelimumab | 1 | T1 | |||
| atezolizumab alone | 1 | T1 | |||
| atezolizumab plus cometinib | 1 | T1 | |||
| Standard of Care (SoC) | 0 | T0 | |||
| BSC | 0 | T0 | |||
| regorafenib | 0 | T0 | T0 | ||